<?xml version="1.0" encoding="UTF-8"?>
<p id="Par1489">
 <bold>Conclusions:</bold> The EVADE study represents an innovative pre-emptive therapy approach to prevent P aeruginosa nosocomial pneumonia in MV patients by utilizing the novel mAb, MEDI3902, thereby offering a new paradigm in P aeruginosa infection management in high-risk patients.
</p>
